Chinese scientists have found out how the H5N1 virus initially invades the mammary glands of dairy cattle and may have ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

South Africa has reported the highly pathogenic H5N1 strain of avian influenza, or bird flu, on two poultry farms in the country, the World Organisation for Animal Health said on Wednesday.

Moderna reports positive results from phase 3 efficacy study of P304 for seasonal influenza vaccine: Cambridge, Massachusetts Wednesday, July 2, 2025, 16:00 Hrs [IST] Moderna, Inc ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna Inc (NASDAQ:MRNA) saw its stock rise 3.8% after announcing that its experimental flu vaccine, mRNA-1010, delivered ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

The CDC's vaccine advisory committee voted to recommend annual flu vaccines but against flu shots containing the preservative ...